澳门在线赌城娱乐在ECCMID 2024上推进传染病保护科学

Real-world effectiveness data on Beyfortus reinforce the impact of passive immunisation protecting infants from RSV hospitalisation

最新的真实世界数据显示，免疫功能低下人群仍有发生COVID-19严重后果的风险

澳门在线赌城娱乐将展示其疫苗的新的临床，现实世界和早期科学数据 & 免疫疗法的投资组合^th 欧洲临床微生物学大会 & 传染病(ECCMID)于2024年4月27日至30日在西班牙巴塞罗那举行. 该公司在此次活动中有19份摘要, 包括四次口头报告和四次迟来的报告, which will highlight the continued need to protect at-risk individuals from the increased burden of common infectious diseases and the important role of long-acting antibodies and vaccines.

数据将呈现以下特点:

• 的有效性的真实数据 Beyfortus (nirsevimab), 长效抗体, 预防呼吸道合胞病毒(RSV)住院
• Updated real-world evidence demonstrating the continued disproportionate burden of COVID-19 感染 on immunocompromised individuals, 强调需要额外的保护
• 西帕韦巴特的药代动力学和安全性数据, 一种在免疫功能低下人群中预防COVID-19的研究性长效抗体
• 早期管道资产研究, including a late-breaking oral presentation on a novel mRNA-VLP vaccine platform and data on a monoclonal antibody to prevent recurrent C. 难相处的 感染

Iskra Reic, 执行副总裁, 疫苗和免疫疗法, 澳门在线赌城娱乐, said: “We are excited to share data at ECCMID showcasing the progress across our early- and late-stage 疫苗和免疫疗法 portfolio and our ambition to deliver long-lasting immunity to protect against infectious diseases with differentiated antibodies and vaccines. 还有澳门第一赌城在线娱乐的创新科学, 澳门第一赌城在线娱乐为澳门第一赌城在线娱乐的预防性治疗方法在减轻呼吸道感染负担方面所取得的成就感到自豪, 新的真实世界数据突出了澳门第一赌城在线娱乐长效抗体的有效性 Beyfortus 预防婴儿因呼吸道合胞病毒住院. 除了, our data provide evidence that immunocompromised individuals continue to face a significant and disproportionate burden from COVID-19, 强调需要额外的保护.”

现实世界的证据突出的影响 Beyfortus 预防rsv相关住院
来自nse - gal的真实世界新数据, 一个研究者发起的, 在西班牙加利西亚社区进行的以人群为基础的三年随访研究, 看看2023/2024年的有效性 Beyfortus 在广泛的婴儿人群中开展免疫接种运动，以减少与呼吸道合胞病毒相关的住院.¹ 这些数据补充了现有的证据，加强了……的高疗效 Beyfortus from clinical trials resulting in protection against hospitalisation for RSV-associated lower respiratory tract 感染 (LRTI).

COVID-19对免疫功能低下者的重大负担
五个报告, 包括一次口服, 是否会强调COVID-19对免疫功能低下人群的持续风险和医疗负担. 数据将包括来自INFORM的最新分析, 英国的一项回顾性健康数据库研究, examining the continued increased risk of severe COVID-19 outcomes in several different immunocompromised populations despite receiving multiple COVID-19 vaccinations.^2-3 来自COVIDRIVE研究平台的真实数据(由id.DRIVE public-private partnership) highlight the disproportionately high prevalence of immunocompromising conditions in SARS-CoV-2-positive hospitalised patients with severe acute respiratory 感染 in Europe.^4-6

澳门在线赌城娱乐在ECCMID期间的重要报告

笔记

Beyfortus
Beyfortus (nirsevimab)是单剂量长效抗体, developed and commercialised in partnership by 澳门在线赌城娱乐 and Sanofi using 澳门在线赌城娱乐’s YTE extended-half-life technology. It is designed to protect infants born during or entering their first RSV season and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.  Beyfortus, 以单剂形式直接提供给新生儿和婴儿, 通过抗体提供快速保护，帮助预防由RSV引起的LRTD, 不需要激活免疫系统.⁷

Beyfortus 可以在RSV季节开始的时候给药.⁷

Beyfortus was granted regulatory designations to facilitate expedited 发展 by several major regulatory agencies around the world. Beyfortus 已被批准在欧盟使用, China and Japan and received approval by the US Food and Drug Administration following a unanimous recommendation by the Antimicrobial Drugs Advisory Committee. Beyfortus is recommended by the Advisory Committee on Immunization Practices for broad infant use and was included in the Vaccines for Children programme in the US.⁷ 来自美国疾病控制和预防中心的早期数据, 在2023/4 RSV季节, Beyfortus 与第一个呼吸道合胞病毒流行季节婴儿与呼吸道合胞病毒相关住院率降低90%相关.⁸

Sipavibart
Sipavibart(原AZD3152)是一种针对COVID-19的研究性长效单克隆抗体(LAAB). Sipavibart was designed to provide broad and potent coverage across Omicron and ancestral viral variants by neutralising spike protein interaction with the host receptor ACE2.⁹

Sipavibart来源于SARS-CoV-2感染后恢复期患者捐献的b细胞. Sipavibart是用和 Evusheld 优化后具有相同的半衰期延长，降低了Fc效应函数和补体C1q结合平台. The reduced Fc effector function aims to minimise the risk of antibody-dependent enhancement of disease - a phenomenon in which virus-specific antibodies promote, 而不是抑制, 感染和/或疾病.¹⁰

Sipavibart于1998年被澳门在线赌城娱乐收购 2022年5月来自RQ生物技术.

sipavibart的安全性和有效性正在全球SUPERNOVA COVID-19预防试验中进行研究, 预计数据将于2024年上半年公布.

澳门在线赌城娱乐
澳门在线赌城娱乐(LSE/STO/Nasdaq: AZN)是一家全球性制药公司, 以科学为主导的澳门第一赌城在线娱乐公司，专注于发现, 发展, 以及肿瘤学处方药的商业化, 罕见疾病, 和澳门第一赌城在线娱乐, 包括心血管, 肾 & 新陈代谢和呼吸 & 免疫学. 总部设在剑桥, UK, 澳门在线赌城娱乐在100多个国家开展业务，其创新药物被全球数百万患者使用. 请访问 澳门在线赌城娱乐.com 并在社交媒体上关注公司 @澳门在线赌城娱乐.

联系人
有关联络投资者关系组的详情，请按 在这里. 对于“媒体联系人”，单击 在这里.

参考文献

1. 马拉等人. 普遍预防尼西维单抗预防因呼吸道合胞病毒引起的婴儿住院. 西班牙加利西亚的一项纵向研究. 口头报告. 34^th ECCMID Global; 29 April 2024; Barcelona, Spain.
2. Dube S等. Individuals with multiple sclerosis are at high risk for COVID-19 hospitalization and death despite high rates of vaccination: results from the England INFORM study. 口头报告. 34th ECCMID Global; 27 April 2024; Barcelona, Spain.
3. Dube S等. 继续d increased risk of COVID-19 hospitalisation and death in immunocompromised individuals despite receipt of ≥4 vaccine doses: updated 2023 results from INFORM, 英国的一项回顾性健康数据库观察性研究. 海报P0409. 34th ECCMID Global; 27 April 2024; Barcelona, Spain.
4. Bollaerts K等. COVIDRIVE: a European public-private partnership for generating real-world evidence on the effectiveness of COVID-19 vaccines. 海报P0380. 34th ECCMID Global; 27 April 2024; Barcelona, Spain.
5. Meeraus W等. 严重急性呼吸道感染患者中免疫功能低下的高发率, 包括SARS-CoV-2:多中心结果, 检测阴性病例对照研究. 海报P0381. 34th ECCMID Global; 27 April 2024; Barcelona, Spain.
6. Meeraus W等. 免疫功能低, cancer and other comorbidities in patients with severe acute respiratory 感染 testing positive versus negative for SARS-CoV-2: a post hoc analysis of COVIDRIVE data from May 2021 to May 2023. 海报P0382. 34th ECCMID Global; 27 April 2024; Barcelona, Spain.
7. Jones JM，等. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices – United States, 2023. 《凡人周刊. 2023;72(34):920-925.
8. Moline HL，等. Early Estimate of Nirsevimab Effectiveness for Prevention of 呼吸 Syncytial Virus–Associated Hospitalization Among Infants Entering Their First 呼吸 Syncytial Virus Season — New Vaccine Surveillance Network, 2023年10月至2024年2月. 《凡人周刊. 2024;73:209–214.
9. Francica JR等人. 1355. The SARS-CoV-2 Monoclonal Antibody AZD3152 Potently Neutralizes Historical and Emerging Variants and is Being Developed for the Prevention and Treatment of COVID-19 in High-risk Individuals. 开放论坛感染Dis. 2023年11月27日;10(增刊2):500.1192. doi: 10.1093 / ofid / ofad500.1192.
10. Van Erp EA，等. fc介导的抗体效应在呼吸道合胞病毒感染和疾病中的作用. 前面Immunol. 2019; 10(3月).